CN100448431C - Oral disintegrated Anfenmame tablet for treating children's cold and its prepn - Google Patents
Oral disintegrated Anfenmame tablet for treating children's cold and its prepn Download PDFInfo
- Publication number
- CN100448431C CN100448431C CNB2005100573220A CN200510057322A CN100448431C CN 100448431 C CN100448431 C CN 100448431C CN B2005100573220 A CNB2005100573220 A CN B2005100573220A CN 200510057322 A CN200510057322 A CN 200510057322A CN 100448431 C CN100448431 C CN 100448431C
- Authority
- CN
- China
- Prior art keywords
- tablet
- coating
- anfenmame
- acetaminophen
- disintegrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a mouth cavity disintegrated Anfenmamei tablet which comprises active components such as acetaminophen, pseudoephedrine hydrochloride and dexmethorphan hydrobromide and adjuvant materials, such as filling agents, disintegrating agents, taste correcting agents, lubricating agents, flow assistants, etc., wherein the taste hiding coating process of main medicines is carried out. The mouth cavity disintegrated Anfenmamei tablet can be rapidly disintegrated in the mouth cavity, and the mouth cavity disintegrated Anfenmamei tablet is particularly suitable for the symptomatic treatment of the cold of children.
Description
Technical field
The present invention relates to a kind of compound recipe coldrex that acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide are formed that contains, can be in the oral cavity disintegrating oral novel form and preparation method rapidly.
Background technology
The common sympton of flu is headache, heating, nasal obstruction, watery nasal discharge, systemic pain etc.It is generally acknowledged that common cold has rhinovirus to cause, owing to still do not have specific drug for virus at present, so the main symptomatic treatment that adopts.It is wide in variety to be used for the anti-compound preparation that cures cold now on the market, from contained main component, medicine commonly used is mainly antiallergic agent, alleviate nasal mucosa congestion and edema medicine, the antipyretic analgesic three major types contains antitussive medicine in the some of them compound recipe coldrex, antiallergic agent is often selected chlorphenamine (chlorphenamine), the medicine that alleviates nasal mucosa hyperemia often selects pseudoephedrine, and antipyretic analgesic is often selected acetaminophen, aspirin for use, and cough medicine is generally selected the central antitussive dextromethorphan hydrobromide for use.
The child since the immunity of health a little less than, very easily catch a cold at the change of season, if untimely treatment, can concurrent bronchitis, pneumonia and even concurrent otitis media, myocarditis etc.In the children's who catches a cold, particularly premature infant, low birthweight infant or congenital heart disease, malnutrition, anemia, child suffering from rickets are arranged because weak, in case pneumonia, often state of an illness threat to life or protracted course of disease.Therefore, need carry out Drug therapy timely.For this special medication colony of child, be very important for it provides suitable specification and dosage form, yet opposite with its market demand be, specialize in flu medication that the child uses and few at present on the market.Authoritative department is spot-check the virgin medication prescription of 1600 shares, kind surplus the medicine that uses reaches 320, children special-purpose medicine less than 1/3rd; In more than the 3000 kind of medicine that circulates on market, be used for child's less than 2%, most medicines are that the child is shared with the adult.When the child used, the prompting of usage, consumption was unclear, mostly is " child is cut down according to the circumstance ", how to subtract, and what subtract, and said and failed to understand.So often cause the infant inappropriate medication, delay treatment is even malpractice influences the infant physical and mental health.Chinese children accounts for 1/3rd of national population, and development child medicine is that society is required.
Oral cavity disintegration tablet is meant not to be needed water or only need use low amounts of water, need not to chew, and tablet places lingual surface, after rapid dissolving of chance saliva or the disintegrate, borrows swallowing act, and medicine can be gone into the tablet of stomach onset.The development of oral cavity disintegration tablet is that new approach has been opened up in emergent treatment, also provide a new method simultaneously for the oral absorption that solves insoluble drug, be applicable to old people and child's oral medication, especially for swallowing inconvenient patient, have more suitable use advantage, thereby found a kind of way of solution for the quality of life of improving patient; Medical treatment for special circumstances such as the geologist of field work drinking-water inconvenience and desert area people provides convenience in addition, and new thinking also is provided for disintegration of tablet degree before solving is bad.Wideling popularize of oral cavity disintegration tablet except that the reform that will promote preparation tablets, also can be made and clinical application generation significant impact pharmaceutical technology, adjuvant, creates bigger economic and social benefit.It is good to the invention provides a kind of preparation mouthfeel, and taste is fragrant and sweet, and dosage is accurate, and the portable coldrex method that is applicable to the child is for the clinical application of children's cold brings a new selection.
Summary of the invention
The present invention is directed to the deficiencies in the prior art part, a kind of child's of being specially adapted for coldrex oral disintegrated Anfenmame tablet is provided, its active component comprises acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and adjuvant comprises IV acrylic resin, Pulvis Talci, disintegrating agent, filler, lubricant, fluidizer, correctives etc.Every contains acetaminophen 80mg, pseudoephedrine hydrochloride 7.5mg, dextromethorphan hydrobromide 2.5mg.Its disintegrating agent can be selected polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, citric acid/sodium bicarbonate, citric acid/sodium carbonate for use, filler is selected from lactose, starch, mannitol, correctives is selected from aspartame, edible essence, sodium chloride etc., lubricant is selected from magnesium stearate, Pulvis Talci, and fluidizer is micropowder silica gel.
The present invention has adopted powder coating technology that principal agent acetyl aminophenol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide are carried out the coating taste masking, here said powder coating is meant every kind of principal agent is carried out coating respectively, also can be to behind three kinds of principal agent mix homogeneously, carry out coating again, adding correctives then corrects residual bitterness, make oral disintegrated Anfenmame tablet have good mouthfeel, coating material mainly is made up of IV acrylic resin, Pulvis Talci and ethanol, and its percentage by weight is respectively 10%, 1%, 89%.Make oral cavity disintegration tablet have good disintegrating property because of adding the method that disintegrating agent combines in adopting, can disintegrate rapidly in the oral cavity, preferably be less than or equal to 1 minute less than 2 minutes its disintegration.
The prescription weight ratio of oral disintegrated Anfenmame tablet:
Filler 1-80%
Acetaminophen 1-40%
Dextromethorphan hydrobromide 1-5%
Pseudoephedrine hydrochloride 1-15%
Correctives 0-10%
Lubricant 0-1%
Fluidizer 0-1%
No. four acrylic resin 0.1-10%
Disintegrating agent 0.1-15%
Preferred formulation weight ratio:
Lactose 1-50%
Starch 1-50%
Acetaminophen 1-40%
Dextromethorphan hydrobromide 1-5%
Pseudoephedrine hydrochloride 1-15%
Aspartame 0-3%
Magnesium stearate 0.1-1%
Micropowder silica gel 0.1-1%
Essence 0-5%
Sodium chloride 0-1%
No. four acrylic resin 0.5-10%
Polyvinylpolypyrrolidone 0.5-6%
The present invention also provides a kind of method for preparing oral cavity disintegration tablet: acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide are carried out powder coating, cross 80 mesh sieves respectively, the recipe quantity lactose and the starch that add by 100 mesh sieves mix again, and it is an amount of to add entry, cross 20 mesh sieves and granulate, 60 ℃ of dryings, 30 mesh sieve granulate add other adjuvant, measure semi-finished product content behind the mix homogeneously, tabletting after meeting the requirements promptly gets oral disintegrated Anfenmame tablet.
Oral cavity disintegration tablet of the present invention at first adopts powder coating technology, and three principal agents are carried out coating cover bitterness, and then wet granulation, add correctives, lubricant, fluidizer etc.The invention provides with acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide is that the mouth of active ingredient collapses novel form, this oral cavity disintegration tablet be particularly suitable for the taking medicine flu child patient of difficulty.Take oral disintegrated Anfenmame tablet the time, medicine is kept in the mouth, about 1-60 is fully disintegrate under the saliva of buccal cavity effect in second, no grittiness, disagreeable tastes such as no bitterness.The characteristics of above-mentioned prescription and technology are: lactose has good compressibility, make the oral cavity disintegration tablet of preparation have good friability, make that tablet has critical external compressive resistance ability preferably in transportation, the polyvinylpolypyrrolidone good fluidity, specific surface area is big, in sheet, be uniformly dispersed, have intensive capillarity, in the rapid inlet port cavity disintegrating tablet of water energy, tablet can be expanded rapidly and produce disintegration preferably, starch had both been made filler, again as in disintegrating agent, with the polyvinylpolypyrrolidone synergism that adds, make the oral cavity disintegration tablet of preparation have good disintegrating property, aspartame is a kind of sweeting agent of extensive use, and its sugariness is 200 times of sucrose, and is soluble in water, with the strawberry essence use in conjunction, in the oral cavity, produce good mouthfeel, make this product accept the magnesium stearate exquisiteness for the flu child easily, lubricity is strong, has good tack, unilateral bright and clean attractive in appearance behind the tabletting, and micropowder silica gel has good fluidizer effect, improves the flowability of material.
Oral disintegrated Anfenmame tablet with fluidized bed coating after, use conventional tablet manufacturing equipment preparation, the product mouthfeel of gained is good, remedies the few defective of coldrex kind that is fit to the child in the market, will produce considerable economic and social benefit.Anfenmame oral cavity disintegration tablet of the present invention is mainly used in the symptomatic treatment of children's cold, takes every day 3 times, each 1-2 sheet.
Description of drawings
Acetaminophen coated granule micro state (amplifying 64 times) before Fig. 1, the coating
Acetaminophen coated granule micro state behind Fig. 2, the coating (amplifying 64 times)
Dextromethorphan hydrobromide coated granule micro state (amplifying 64 times) before Fig. 3, the coating
Dextromethorphan hydrobromide coated granule micro state behind Fig. 4, the coating (amplifying 64 times)
Pseudoephedrine hydrochloride coated granule micro state (amplifying 64 times) before Fig. 5, the coating
Pseudoephedrine hydrochloride coated granule micro state behind Fig. 6, the coating (amplifying 64 times)
Specific embodiment
The particulate preparation of embodiment 1 principal agent powder coating
As solvent, add the IV acrylic resin with ethanol, as antiplastering aid, coating fluid prescription is by weight with Pulvis Talci:
Acrylic resin IV number 10%
Ethanol 89%
Pulvis Talci 1%
Its preparation technology is as follows: it is standby that the crude drug mechanical activation comminution is also crossed 100 mesh sieves; Get the dehydrated alcohol of an amount of (by above-mentioned weight ratio), add the IV acrylic resin while stirring, till dissolving fully; Take by weighing the Pulvis Talci of recipe quantity, be added in the IV acrylic resin alcoholic solution, keep stirring; Medicine is added in the fluidized-bed coating machine, and best inlet temperature is 30 ℃, requires medicine is carried out coating according to the equipment operation, and (weightening finish of acetaminophen coating should reach about 25% until the coating weightening finish of stipulating; The dextromethorphan hydrobromide coating should increase weight and reach about 40%; The weightening finish of pseudoephedrine hydrochloride coating should reach about 50%); Stop into coating solution, open drying, baking temperature is 30 ℃, dry 30min; Discharging is with 80 mesh sieve granulate; Measure the content of coating powder, standby.
In order further to understand the particulate state of coated drugs, used optical microscope to amplify 64 times, observe the particulate micro state of drug coating, the results are shown in accompanying drawing 1, accompanying drawing 2, accompanying drawing 3, accompanying drawing 4, accompanying drawing 5, accompanying drawing 6.
The result that microscopically is observed shows: be covered one deck clothing film or with the inter-adhesive one-tenth larger particles of the small crystalline particle of a plurality of medicines of drug powder behind the coating, its outer bag again by one deck, coating fluid prescription that visible employing is selected and fluidized bed coating technology can reach the purpose to the taste masking of drug target powder coating.
Embodiment 2 is a principal agent with acetaminophen coating powder, pseudoephedrine hydrochloride coating powder, dextromethorphan hydrobromide coating powder, and other compositions are that the prescription that adjuvant prepares oral disintegrated Anfenmame tablet is:
Acetaminophen coating powder contains acetaminophen 80g
The hydrochloric pseudoephedrine 7.5g of pseudoephedrine hydrochloride coating powder
The hydrogeneous bromic acid dextromethorphan of dextromethorphan hydrobromide coating powder 2.5g
Lactose 150g
Starch 27g
Polyvinylpolypyrrolidone 30g
Strawberry essence is an amount of
Aspartame 15g
Sodium chloride 6g
Magnesium stearate 3g
Micropowder silica gel 3g
1000
Tabletting adopts conventional tablet pharmaceutical equipment commonly used, its concrete preparation method is as follows: with acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide coating powder, cross 80 mesh sieves respectively, the recipe quantity lactose and the starch that add by 100 mesh sieves mix again, it is an amount of to add entry, cross 20 mesh sieves and granulate 60 ℃ of dryings, 30 mesh sieve granulate, add other adjuvant, measure semi-finished product content behind the mix homogeneously, the rotary tablet machine tabletting is used in the back that meets the requirements, and promptly gets oral disintegrated Anfenmame tablet.
The oral disintegrated Anfenmame tablet of gained, hardness are about 4kg, friability (Chinese Pharmacopoeia 2000 editions) 1.5%, and disintegration time is 50 seconds in the oral cavity.
Embodiment 3
Acetaminophen coating powder contains acetaminophen 80g
The hydrochloric pseudoephedrine 7.5g of pseudoephedrine hydrochloride coating powder
The hydrogeneous bromic acid dextromethorphan of dextromethorphan hydrobromide coating powder 2.5g
Mannitol 300g
Microcrystalline Cellulose 10g
Low-substituted hydroxypropyl cellulose 50g
Essence is an amount of
Aspartame 15g
Magnesium stearate 3g
Micropowder silica gel 3g
1000
Tabletting can adopt direct compression process, its concrete preparation method is as follows: with acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide coating powder, cross 80 mesh sieves respectively, add recipe quantity other adjuvants except that lubricant and fluidizer again, mixed 40 minutes, add lubricant and fluidizer with V-Mixer by 100 mesh sieves, mixed 5 minutes, measure semi-finished product content, the rotary tablet machine tabletting is used in the back that meets the requirements, and promptly gets oral disintegrated Anfenmame tablet.
The oral disintegrated Anfenmame tablet of gained, hardness are about 3.5kg, friability (Chinese Pharmacopoeia 2000 editions) 3%, and disintegration time is 30 seconds in the oral cavity.
Embodiment 4
Acetaminophen coating powder contains acetaminophen 80g
The hydrochloric pseudoephedrine 7.5g of pseudoephedrine hydrochloride coating powder
The hydrogeneous bromic acid dextromethorphan of dextromethorphan hydrobromide coating powder 2.5g
Mannitol 250g
Starch 10g
Crosslinked carboxymethyl fecula sodium 50g
Sodium bicarbonate 10g
Citric acid 7.5g
Essence is an amount of
Aspartame 15g
Magnesium stearate 3g
Micropowder silica gel 3g
1000
Tabletting can adopt direct compression process, its concrete preparation method is as follows: with acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide coating powder, cross 80 mesh sieves respectively, add recipe quantity other adjuvants except that lubricant and fluidizer again, mixed 40 minutes, add lubricant and fluidizer with V-Mixer by 100 mesh sieves, mixed 5 minutes, measure semi-finished product content, the rotary tablet machine tabletting is used in the back that meets the requirements, and promptly gets oral disintegrated Anfenmame tablet.
The oral disintegrated Anfenmame tablet of gained, hardness are about 3.5kg, friability (Chinese Pharmacopoeia 2000 editions) 3.5%, and disintegration time is 25 seconds in the oral cavity.
Claims (7)
1, a kind of oral disintegrated Anfenmame tablet, acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and pharmaceutic adjuvant by effective therapeutic dose are formed, the weight ratio of acetaminophen, pseudoephedrine hydrochloride and dextromethorphan hydrobromide is 80: 7.5: 2.5, it is characterized in that:
A contains the coating material that active constituent is carried out coating, and its coating material is made up of IV acrylic resin, Pulvis Talci and ethanol, and percentage by weight is respectively 10%, 1%, 89%;
In the b pharmaceutic adjuvant, filler accounts for the 1-80% of tablet weight, and disintegrating agent accounts for the 0.1-15% of sheet weight;
This tablet of c in the oral cavity disintegration time less than 2 minutes.
2, oral disintegrated Anfenmame tablet according to claim 1 is characterized in that: acetaminophen 80mg, pseudoephedrine hydrochloride 7.5mg, dextromethorphan hydrobromide 2.5mg.
3, oral disintegrated Anfenmame tablet according to claim 1 is characterized in that: filler is selected from least a in lactose, mannitol, starch, the microcrystalline Cellulose.
4, oral disintegrated Anfenmame tablet according to claim 1 is characterized in that: disintegrating agent is selected from least a in polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, crosslinked carboxymethyl fecula sodium, sodium carbonate/citric acid, the sodium bicarbonate/citric acid.
5, oral disintegrated Anfenmame tablet according to claim 1, its pharmaceutic adjuvant also comprises lubricant.
6, a kind of preparation method of oral disintegrated Anfenmame tablet, wherein said disintegrating tablet is made up of following material, per 1000:
Acetaminophen coating powder contains acetaminophen 80g
The hydrochloric pseudoephedrine 7.5g of pseudoephedrine hydrochloride coating powder
The hydrogeneous bromic acid dextromethorphan of dextromethorphan hydrobromide coating powder 2.5g
Lactose 150g
Starch 27g
Polyvinylpolypyrrolidone 30g
Strawberry essence is an amount of
Aspartame 15g
Sodium chloride 6g
Magnesium stearate 3g
Micropowder silica gel 3g,
Its preparation process mainly is made up of following steps:
1) the IV acrylic resin is dissolved, adds Pulvis Talci fully with ethanol, stir, get coating solution, wherein IV acrylic resin, Pulvis Talci and alcoholic acid percentage by weight are respectively 10%, 1%, 89%;
2), acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide are carried out powder coating, with above-mentioned coating solution coated granule;
3), coated granule is crossed 80 mesh sieves respectively, add lactose and starch by the recipe quantity of 100 mesh sieves, mix, it is an amount of to add entry, crossing 20 mesh sieves granulates, 60 ℃ of dryings are crossed 30 mesh sieves, granulate, add other adjuvant again, measure semi-finished product content behind the mix homogeneously, the rotary tablet machine tabletting is used in the back that meets the requirements, and promptly gets oral disintegrated Anfenmame tablet.
7, a kind of preparation method of oral disintegrated Anfenmame tablet, wherein said disintegrating tablet is made up of following material, per 1000:
Acetaminophen coating powder contains acetaminophen 80g
The hydrochloric pseudoephedrine 7.5g of pseudoephedrine hydrochloride coating powder
The hydrogeneous bromic acid dextromethorphan of dextromethorphan hydrobromide coating powder 2.5g
Mannitol 300g
Microcrystalline Cellulose 10g
Low-substituted hydroxypropyl cellulose 50g
Essence is an amount of
Aspartame 15g
Magnesium stearate 3g
Micropowder silica gel 3g,
Its preparation process mainly is made up of following steps:
1) the IV acrylic resin is dissolved, adds Pulvis Talci fully with ethanol, stir, get coating solution, wherein IV acrylic resin, Pulvis Talci and alcoholic acid percentage by weight are respectively 10%, 1%, 89%;
2), acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide are carried out powder coating, with above-mentioned coating solution coated granule;
3), coated granule is crossed 80 mesh sieves respectively, add recipe quantity other adjuvants except that magnesium stearate lubricant and fluidizer micropowder silica gel again by 100 mesh sieves, mixed 40 minutes with V-Mixer, add lubricant and fluidizer, mixed 5 minutes, measure semi-finished product content, the rotary tablet machine tabletting is used in the back that meets the requirements, and promptly gets oral disintegrated Anfenmame tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100573220A CN100448431C (en) | 2005-10-17 | 2005-10-17 | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100573220A CN100448431C (en) | 2005-10-17 | 2005-10-17 | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1771915A CN1771915A (en) | 2006-05-17 |
| CN100448431C true CN100448431C (en) | 2009-01-07 |
Family
ID=36759170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100573220A Expired - Fee Related CN100448431C (en) | 2005-10-17 | 2005-10-17 | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100448431C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101436516B1 (en) * | 2007-07-23 | 2014-09-02 | 주식회사태평양제약 | Dispersible tablet containing coated pellet and preparation method thereof |
| CN101467988B (en) * | 2007-12-27 | 2014-07-09 | 北京德众万全医药科技有限公司 | Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof |
| CN103169706B (en) * | 2011-12-26 | 2016-08-03 | 重庆医药工业研究院有限责任公司 | A kind of compound oral disintegrating tablet containing acetaminophen and dextromethorphan |
| CN113057950A (en) * | 2020-01-02 | 2021-07-02 | 上海信谊万象药业股份有限公司 | Oral pediatric paracetamol, atificial cow-bezoar and chlorphenamine maleate granule preparation and preparation process thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586483A (en) * | 2004-07-12 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method |
| CN1615866A (en) * | 2004-09-21 | 2005-05-18 | 石家庄制药集团欧意药业有限公司 | Anti-cold medicine soft capsule and its preparing method |
| CN1626080A (en) * | 2003-12-11 | 2005-06-15 | 江苏晨牌药业有限公司 | Paracetamol Pseudoephedrine desintegration piece and preparation method |
| CN1634061A (en) * | 2004-10-11 | 2005-07-06 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process |
-
2005
- 2005-10-17 CN CNB2005100573220A patent/CN100448431C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626080A (en) * | 2003-12-11 | 2005-06-15 | 江苏晨牌药业有限公司 | Paracetamol Pseudoephedrine desintegration piece and preparation method |
| CN1586483A (en) * | 2004-07-12 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method |
| CN1615866A (en) * | 2004-09-21 | 2005-05-18 | 石家庄制药集团欧意药业有限公司 | Anti-cold medicine soft capsule and its preparing method |
| CN1634061A (en) * | 2004-10-11 | 2005-07-06 | 贵阳云岩西创药物科技开发有限公司 | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771915A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101159617B1 (en) | Tablet quickly disintegrating in oral cavity | |
| ES2713330T3 (en) | Dry-coated tablet that disintegrates orally | |
| WO2002030400A1 (en) | Solid preparations | |
| JP4284017B2 (en) | Solid preparation | |
| WO1993015724A1 (en) | Fast soluble tablet | |
| CN103402497A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| CN101299996A (en) | Oral compositions containing a salivation inducing agent | |
| CN105142618A (en) | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration | |
| JPWO2002032403A1 (en) | Oral fast disintegrating pharmaceutical composition and method for producing the same | |
| JPH1133084A (en) | Intraoral soluble type tablet and manufacture thereof | |
| CN100448431C (en) | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn | |
| JPH1135451A (en) | Intraoral dissolving type tablet and its production | |
| JP2003034655A (en) | Fast degradable solid tablet | |
| JP2007509937A (en) | Controlled release analgesic suspension | |
| CN101081218A (en) | Rapid-disintegrated oral film and method for making same | |
| JP5201837B2 (en) | Orally disintegrating tablets | |
| Raj | Formulation and In-vitro evaluation of Voglibose Dispersible tablets | |
| JPH1135486A (en) | Solid pharmaceutical preparation | |
| JP2007509936A (en) | Controlled release analgesic suspension | |
| CN101716344A (en) | Pholcodine-containing compound pharmaceutical preparation for treating cold | |
| JP3967767B1 (en) | Method for producing intraoral rapidly disintegrating tablet | |
| CN100536829C (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| JPH11116465A (en) | Rapidly dissolvable preparation and its production | |
| CN104434860A (en) | Ambroxol hydrochloride osmotic pump type pharmaceutical composition prepared by inclusion process | |
| RU2166937C1 (en) | Paracetamol-base drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Free format text: FORMER OWNER: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. GUANGXI HUAHONG PHARMACEUTICAL CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Co-patentee after: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee after: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Co-patentee after: HUAHONG PHARMACEUTICAL Co.,Ltd. GUANGXI ZHUANG AUTONOMOUS REGION Address before: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee before: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Co-patentee before: Guangxi Huahong Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101115 Address after: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Co-patentee after: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee after: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee before: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Co-patentee before: HUAHONG PHARMACEUTICAL Co.,Ltd. GUANGXI ZHUANG AUTONOMOUS REGION |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090107 Termination date: 20141017 |
|
| EXPY | Termination of patent right or utility model |